Log in to search using one of your social media accounts:

 

CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation Sponsor:   Weill Medical College of Cornell University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Conditions:   Acute Biphenotypic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Blasts Under 10 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive ;   Cytogenetic Abnormality;   High Risk Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts;   Pancytopenia;   Refractory Anemia Interventions: &nb...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation Sponsor:   Weill Medical College of Cornell University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractIn contrast to the evidence regarding azacitidine (Aza), there is limited knowledge about the combination of decitabine (DAC) and donor lymphocyte infusions as salvage therapy for relapse after allogeneic stem cell transplantation (allo-SCT) so far. We retrospectively analyzed data of 36 patients with hematological (n = 35) or molecular relapse (n = 1) of acute myeloid leukemia (AML,n = 29) or myelodysplastic syndrome (MDS,n = 7) collected from 6 German transplant centers. Patients were treated with a median of 2 cycles DAC (range, 1 to 11). DAC was the first ...
Source: Annals of Hematology - Category: Hematology Source Type: research
Publication date: Available online 29 December 2017 Source:Journal of Geriatric Oncology Author(s): Marlise R. Luskin, Gregory A. Abel The myelodysplastic syndromes (MDS) are a varied group of hematologic neoplasms that lead to bone marrow failure, and also carry a risk of progression to acute myeloid leukemia. Patients with MDS suffer significant impairments to both their quality of life and survival. Age is the dominant risk factor for the development of MDS, with a median age at diagnosis over 70years. Consequently, patients with MDS frequently have concurrent comorbidities and/or frailty which may be coincident or rel...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
Haplo/cord transplantation combines an umbilical cord blood (UCB) graft with CD34-selected haploidentical cells and results in rapid hematopoietic recovery followed by durable UCB engraftment. We compared outcomes of transplants in older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) who received either HLA-matched unrelated donor cells (MUD) or haplo/cord grafts. Between 2007 and 2013, 109 adults ages 50 and older underwent similar reduced intensity conditioning (RIC) with fludarabine and melphalan and antibody-mediated T-cell depletion for AML (n=83) or high risk MDS (n=26) follow...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Minimizing toxicity while maximizing efficacy is a goal that has proven challenging in patients who are considered high risk for relapse after allogeneic hematopoietic cell transplantation (HCT), particularly in older individuals. The median patient age at diagnosis of myelodysplastic syndromes (MDS) is in the early 70s [1] and for acute myeloid leukemia (AML) in the mid-to-late 60s (SEER statistics, 2005 to 2009), and typically reduced-intensity conditioning regimens are used in preparation for HCT.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Relapse remains the main obstacle for patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation and novel therapeutic strategies are urg... Author: VJHemOnc Added: 12/18/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
The outcome for patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) after allogeneic stem cell transplantation remains poor. In this interview, Charles Craddock, CBE, FRCP (U... Author: VJHemOnc Added: 12/18/2017
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
More News: Acute Leukemia | Leukemia | Myelodysplastic Syndrome | Transplants